Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
57
FATE Quote, Financials, Valuation and Earnings
Last price:
$1.37
Seasonality move
:
3.56%
Day range:
$1.33 - $1.40
52-week range:
$0.66 - $1.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.73x
P/B ratio:
0.68x
Volume:
1.3M
Avg. volume:
1.7M
1-year change:
-10.46%
Market cap:
$158M
Revenue:
$13.6M
EPS (TTM):
-$1.32
Analysts' Opinion
-
Consensus RatingFate Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.94, Fate Therapeutics, Inc. has an estimated upside of 260.91% from its current price of $1.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.37.
Fair Value
-
According to the consensus of 11 analysts, Fate Therapeutics, Inc. has 260.91% upside to fair value with a price target of $4.94 per share.
FATE vs. S&P 500
-
Over the past 5 trading days, Fate Therapeutics, Inc. has overperformed the S&P 500 by 24.86% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Fate Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fate Therapeutics, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Fate Therapeutics, Inc. reported revenues of $1.7M.
Earnings Growth
-
Fate Therapeutics, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Fate Therapeutics, Inc. reported earnings per share of -$0.27.
Enterprise value:
21.9M
EV / Invested capital:
--
Price / LTM sales:
22.73x
EV / EBIT:
--
EV / Revenue:
3.06x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$7.5M
Return On Assets:
-38.08%
Net Income Margin (TTM):
-2187.11%
Return On Equity:
-53.28%
Return On Invested Capital:
-41.23%
Operating Margin:
-1995.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $106.2M | $13.4M | $7.1M | $3.1M | $1.7M | |
| Gross Profit | $88M | -$5.6M | -$7.5M | -$1.5M | -$1.5M | |
| Operating Income | -$206.9M | -$196.6M | -$160M | -$52.4M | -$34.7M | |
| EBITDA | -$188.6M | -$177.6M | -$145.3M | -$47.8M | -$31.5M | |
| Diluted EPS | -$1.77 | -$1.65 | -$1.32 | -$0.40 | -$0.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $693.7M | $535.3M | $364.2M | $310.3M | $221.3M | |
| Total Assets | $984.6M | $749.3M | $543.8M | $495M | $343.7M | |
| Current Liabilities | $91.9M | $103.9M | $41.3M | $37.4M | $28.1M | |
| Total Liabilities | $254.2M | $231.3M | $141M | $132.6M | $109.6M | |
| Total Equity | $730.3M | $518M | $402.8M | $362.3M | $234.1M | |
| Total Debt | $109.1M | $105.2M | $99M | $92.1M | $74.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$171M | -$131.7M | -$110.6M | -$29.4M | -$24.4M | |
| Cash From Investing | $120.4M | $34.8M | $106.4M | $25.5M | $21.3M | |
| Cash From Financing | $1.8M | $96.6M | $6.9M | -- | $2.5M | |
| Free Cash Flow | -$183.7M | -$132.5M | -$115.4M | -$29.9M | -$26.6M | |
FATE
Sector
Market Cap
$158M
$25.8M
Price % of 52-Week High
70.62%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
2.93%
-1.67%
1-Year Price Total Return
-10.46%
-21.92%
Beta (5-Year)
2.246
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.21
200-day SMA
Buy
Level
$1.16
Bollinger Bands (100)
Buy
Level
1 - 1.36
Chaikin Money Flow
Buy
Level
5M
20-day SMA
Buy
Level
$1.20
Relative Strength Index (RSI14)
Buy
Level
64.88
ADX Line
Buy
Level
23.54
Williams %R
Sell
Level
-8.3333
50-day SMA
Buy
Level
$1.12
MACD (12, 26)
Buy
Level
0.31
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.2597)
Sell
CA Score
(Annual)
Level (-1.2803)
Sell
Beneish M-Score
(Annual)
Level (1.5227)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.2095)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, FATE has received 5 Buy ratings 6 Hold ratings, and 0 Sell ratings. The FATE average analyst price target in the past 3 months is $4.94.
-
Where Will Fate Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fate Therapeutics, Inc. share price will rise to $4.94 per share over the next 12 months.
-
What Do Analysts Say About Fate Therapeutics, Inc.?
Analysts are divided on their view about Fate Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fate Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Fate Therapeutics, Inc.'s Price Target?
The price target for Fate Therapeutics, Inc. over the next 1-year time period is forecast to be $4.94 according to 11 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is FATE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fate Therapeutics, Inc. is a Hold. 6 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of FATE?
You can purchase shares of Fate Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fate Therapeutics, Inc. shares.
-
What Is The Fate Therapeutics, Inc. Share Price Today?
Fate Therapeutics, Inc. was last trading at $1.37 per share. This represents the most recent stock quote for Fate Therapeutics, Inc.. Yesterday, Fate Therapeutics, Inc. closed at $1.37 per share.
-
How To Buy Fate Therapeutics, Inc. Stock Online?
In order to purchase Fate Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get FATE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
FATE
Sector
P/E ratio
--
23.35x
PEG ratio
--
-0.01x
P/B ratio
0.68x
1.78x
Price / LTM sales
22.73x
1.55x
Growth Metrics
FATE
Sector
Revenue growth
-43.36%
3.74%
Earnings growth
33.05%
11.14%
Revenue (5-year growth)
5%
6.38%
Earnings forecast
-$0.27
-$0.19
Profitability
FATE
Sector
Profitability FY 2024
-$5.3M
$2.6M
Return on invested capital
-41.23%
-32.91%
Return on assets
-38.08%
-29.56%
Return on equity
-53.28%
-38.66%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
4
Estimated Next Earnings Date
Feb
12
Balance Sheet
FATE
Sector
Total cash
$215.4M
$25.2M
Short term investments
$243M
$24.1M
Total assets
$440.7M
$72.8M
Long term debt
$74.5M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 21.1% over the past day.
Buy
90
TCMD alert for Feb 19
Tactile Systems Technology, Inc. [TCMD] is up 17.83% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 17.31% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
